Is Your SIBO Breath Test Really Reliable? Why Standard Testing May Miss the Mark in IBS

By Rohan Smith · Functional & Nutritional Medicine, Adelaide · Published April 16, 2026

What Is SIBO Breath Testing and How Does It Work?

SIBO breath testing measures hydrogen (H₂) and methane (CH₄) gases in your exhaled breath after you drink a sugar solution — typically either lactulose or glucose. The principle is straightforward: bacteria in the small intestine ferment these sugars and produce gases that are absorbed into the bloodstream and exhaled through the lungs.

According to the North American Consensus established by Rezaie et al. in 2017, a positive result requires a hydrogen rise of ‚â•20 parts per million (ppm) above baseline within 90 minutes, or methane levels ‚â•10 ppm at any point during the test.^[1] Twenty-six of 28 consensus statements reached expert agreement in that landmark publication.

On paper, this sounds reliable. In practice, it's considerably more complicated — and the limitations have significant implications for anyone who's been diagnosed with (or told they don't have) SIBO based on this test alone.

Why Breath Test Results Can Be Misleading in IBS

A systematic review and meta-analysis by Shah et al. found that IBS patients were 3.7 times more likely to test positive for SIBO than healthy controls (OR 3.7, 95% CI 2.3–6.0), with prevalence reaching 35.5% by breath test but only 13.9% by jejunal aspirate culture.^[7] That discrepancy — breath tests finding SIBO at nearly triple the rate of the gold standard — raises questions about what the test is actually measuring.

Several factors may explain the gap. Rapid oro-cecal transit, common in IBS-D, can push lactulose into the large intestine before 90 minutes, producing a fermentation peak that looks like small intestinal overgrowth but actually reflects normal colonic bacteria. Ghoshal and Srivastava's critical review noted that the "early-peak" criterion on lactulose breath testing is "fallacious" precisely because of this transit-time confound.^[14]

Rana et al. demonstrated this vividly: lactulose breath testing was positive in 34.3% of IBS patients and 30% of controls — virtually indistinguishable — while its positive predictive value against glucose breath testing was only 11.7%.^[5] When a test can't meaningfully distinguish patients from healthy individuals, its diagnostic value is limited.

The Threshold Problem: Which Criteria, Which Result?

Even when the test is performed correctly, interpretation varies depending on which diagnostic guidelines the clinician follows. Baker et al. compared the North American Consensus protocol against a traditional method in over 6,000 patients — the largest head-to-head comparison to date. Positive rates differed significantly: 39.5% under the North American protocol versus 29.7% under the modified Rome criteria (P<0.001), driven primarily by differences in methane interpretation.^[2]

A landmark 2026 real-world study involving 3,004 patients introduced three-gas testing, adding hydrogen sulfide to the standard hydrogen–methane panel. H₂S levels ≥2 ppm correlated significantly with diarrhea (P<0.0001), urgency (P=0.003), and abdominal pain (P=0.01). Notably, SIBO positivity in this cohort was 27% by lactulose but only 7.3% by glucose — nearly a fourfold discrepancy in the same population.^[12]

Gandhi et al.'s meta-analysis added further nuance: methane-positive SIBO was 3.1 times more prevalent in constipation-dominant IBS versus diarrhea-dominant IBS (OR 3.1, P=0.0001), suggesting that gas phenotype, not just presence, matters clinically.^[11]

Beyond Breath Testing: A Comprehensive Assessment

When breath testing has these limitations, what does a more complete clinical picture involve? In functional medicine, the approach typically involves multiple complementary assessments rather than relying on a single test.

For more on the functional medicine approach to SIBO, including testing and treatment options, see our comprehensive SIBO guide.

Why SIBO Keeps Coming Back

Perhaps the most important clinical insight from the SIBO literature isn't about diagnosis — it's about recurrence. Lauritano et al. tracked patients after successful rifaximin eradication and found that SIBO recurred in 12.6% at 3 months, 27.5% at 6 months, and 43.7% at 9 months. Independent risk factors included chronic proton pump inhibitor (PPI) use (OR 3.52) and history of appendectomy (OR 5.9).^[20]

Why does it come back? The migrating motor complex (MMC) — the "cleansing wave" that sweeps residual bacteria from the small intestine between meals — appears to be a primary driver. Pimentel et al. found that IBS patients with SIBO had dramatically fewer phase III MMC events (0.7 vs 2.2 per 4 hours, P<0.000001) and shorter event duration (305 vs 428 seconds, P<0.001). Eradication of SIBO partially normalised MMC frequency.^[17]

Talamantes et al. confirmed this relationship using wireless motility capsule testing in 196 patients, finding that intestinal methanogen overgrowth (IMO) was associated with significantly delayed small bowel transit time (5h 15m vs 4h 32m, P=0.021) and colonic transit time (44h 23m vs 28h 51m, P=0.030).^[18]

This is why addressing motility — not just eradicating bacteria — may be essential for long-term resolution. As Knez et al. emphasised in their 2024 review, repeated antibiotic therapy without motility restoration risks driving resistance while leaving the underlying mechanism intact.^[21]